[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fine-lines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fine-lines":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,80,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100625354","phase-4-assess-injectable-hyaluronic-acid-gel-for-the-treatment-of-volume-loss-skin-laxity-and-fine-lines-100625354",false,"NCT07421544","Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines","A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines","Inclusion Criteria:\n\n1. Adult subjects aged 30 to 75 years at the time of screening\u002Fbaseline.\n2. Fitzpatrick skin types I-VI.\n3. Investigator classification of the subject as having mild-to-moderate facial aging in at least one (≥1) facial areas, defined as meeting the following scale criteria at screening\u002Fbaseline:\n\n   Midface Volume Deficit Scale (Appendix A): score of 2-3 Nasolabial Folds Severity Scale (Appendix B): score of 2 or 3\n4. Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.\n5. Willing and able to provide written informed consent form and photography release for research, publication, and\u002For commercial use.\n6. In good general health as determined by the investigator based on medical history and clinical judgment.\n7. Willing to maintain the study-specified skincare regimen and refrain from initiating new topical or procedural facial treatments during the study period.\n8. For subjects of childbearing potential, a negative urine pregnancy test at screening\u002Fbaseline and at all subsequent visits, as applicable.\n9. Female subjects of childbearing potential must agree to use an acceptable method of contraception throughout the study and must have been using systemic contraception consistently for at least 30 days prior to enrollment, unless they meet criteria for non-childbearing potential.\n\nSubjects are considered not of childbearing potential if they meet one of the following:\n\nHistory of hysterectomy or bilateral oophorectomy, or No menses for at least 12 consecutive months without an alternative medical cause.\n\nOr, if of childbearing potential, must agree to use an effective form of contraception during the course of the study. Acceptable methods include:\n\nOral contraceptive pill, injection, implant, patch, vaginal ring, or intrauterine device (IUD) Intrauterine coil Bilateral tubal ligation Hysterectomy Barrier method used with an additional form of contraception (e.g., spermicide, sponge, or condom) Abstinence (must agree to use a barrier method if sexual activity begins during the study) Partner with a vasectomy (if not, subject must agree to use a barrier methods\n\nExclusion Criteria:\n\n1. Prior use of injectable treatments to the face within the past 12 months, including HA fillers and biostimulator injectables, i.e. calcium hydroxyapatite, poly-L-lactic acid (e.g., Sculptra, Radiesse), platelet-rich plasma (PRP), platelet-rich fibrin (PRF) Any facial surgical procedure (e.g., facelift, facial implants) within the past 12 months.\n2. Use of neuromodulators (e.g., botulinum toxin) to the face or neck within 6 months prior to study enrollment or at any time during the study period.\n3. Use of dermal fillers of any kind during the study period.\n4. Use of at-home energy-based devices intended for rejuvenation or fibroblastic\u002Fcollagen stimulation within 30 days prior to treatment and during the study period.\n5. Use of systemic retinoids (e.g., isotretinoin) within 3 months prior to enrollment\n6. Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.\n7. Plants to become pregnant during the study period, or current breastfeeding.\n8. Known allergy or hypersensitivity to lidocaine, tetracaine, or other local anesthetics.\n9. Coagulation disorders or use of anticoagulants or antiplatelet medications that cannot be safely discontinued per investigator discretion.\n10. History of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma, dermatomyositis).\n11. Current or recent use (within the past 3 months) of systemic immunosuppressive medications.\n12. Any uncontrolled systemic condition that may increase risk or interfere with study participation, including but not limited to poorly managed diabetes, thyroid dysfunction, or cardiovascular disease.\n13. Clinically significant neurological, psychological or psychiatric conditions, or any condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.\n14. Current use of tobacco or nicotine-containing products, or use within 6 months prior to enrollment; participants must also agree to abstain from tobacco and nicotine-containing products for the duration of the study.\n15. Participation in any other interventional clinical study within 30 days prior to enrollment or during the course of this study.\n16. Unwillingness to refrain from undergoing any additional aesthetic treatments to the face and neck (e.g., lasers, injectables, energy-based devices, cosmeceuticals, etc.) from screening through the end of the study period.\n17. Use of sunless tanner or have spray tanned in the treatment areas 4 weeks prior to study treatment.\n18. History of keloids or scarring\u002Ftattoos in the treatment area.",true,"ALL","30 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.",[28,29,30,31],"Fine Lines","Wrinkle","Facial Laxity","Volume Loss","NOT_YET_RECRUITING","2026-02-12",{"date":35,"type":36},"2026-02-19","ACTUAL",{"date":38,"type":22},"2026-03-01",{"date":40,"type":22},"2026-07-01",{"name":42,"class":43},"Goldman, Butterwick, Fitzpatrick and Groff","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100619355","clinical-trial-to-assess-the-efficacy-and-safety-of-a-cosmetic-product-in-individuals-showing-signs-of-cutaneous-aging-100619355","NCT07343544","Clinical Trial to Assess the Efficacy and Safety of a Cosmetic Product in Individuals Showing Signs of Cutaneous Aging.","Estudio clínico Para Evaluar Los Efectos y la Seguridad de un Producto cosmético en Sujetos Con Signos de Envejecimiento cutáneo.","SkinMeter","Inclusion Criteria:\n\n* Female participants.\n* Age between 35 and 60 years.\n* All skin types (combination, oily, dry, and\u002For normal).\n* Skin condition: 50% sensitive skin and 50% normal skin.\n* Visible signs of facial skin aging (mild\u002Fmoderate wrinkles and\u002For pigmentation spots).\n* Willingness to participate voluntarily and provide written informed consent.\n* Ability to understand the study objectives and procedures.\n* Good general health (physical and mental).\n* Availability to attend all scheduled visits at the research center.\n* Discontinuation of anti-aging products on the experimental area (face) at least 7 days prior to study start.\n* Commitment not to change facial hygiene routines during the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* History of allergy to cosmetic products and\u002For dietary supplements.\n* Known allergy or hypersensitivity to any component of the product.\n* History or current diagnosis of cancer.\n* Active skin diseases or infections in the experimental area.\n* Recent or planned surgical or aesthetic interventions in the experimental area Medical-aesthetic treatments on the face within the last 6 months (e.g., botulinum toxin, hyaluronic acid, laser, radiofrequency, HIFU, deep chemical peels, microneedling with actives).\n* Relevant dermatological conditions in the experimental area (eczema, psoriasis, allergic\u002Fcontact dermatitis, etc.).\n* Use of topical or systemic medications affecting the skin (retinoids, antibiotics, corticosteroids) within the last 3 months.\n* Current or planned use of supplements that may affect skin health (collagen, antioxidant vitamins A\u002FC\u002FE, zinc, omega-3, oral probiotics\u002Fprebiotics).\n* Systemic diseases such as autoimmune disorders (rheumatoid arthritis, lupus, multiple sclerosis), chronic viral infections (HIV, hepatitis B\u002FC), or severe metabolic diseases.\n* Use of any product other than the study product on the experimental area during the study.\n* Planned significant changes in health habits during the study (diet, physical activity, structured exercise programs).\n* Recent or planned changes in hormonal contraceptives.\n* Sun or UVA exposure during the study.\n* Participation in another clinical study involving the same experimental area\n* Application of any product on the experimental area on the day of study initiation.\n* Any medical condition, at the investigator's discretion, that may interfere with protocol adherence or participant safety.","FEMALE","35 Years","60 Years",{"count":57,"type":22},45,[59],"NA","This clinical study investigates the effects and safety of a topical cosmetic product containing postbiotics (Bifida ferment extract and Pediococcus ferment extract) in women aged 35-60 with visible signs of skin aging.\n\nThe study is a 3-month, single-center, intra-subject controlled trial involving 45 Caucasian women with sensitive or normal skin. Participants will apply 1 ml of the product twice daily. Clinical evaluations will be conducted at baseline and at 1 month, 2 months, and 3 months, using validated dermatological scales and non-invasive instruments (AEVA3D, Mexameter®, MoistureMap®, Cutometer®, Tewameter®, Clarius®, Glossymeter®).\n\nSafety will be assessed through systematic monitoring of adverse events, with serious adverse events expected to remain below 1%. Subjective perception will be evaluated via structured questionnaires.",[62,63,28,64,65],"Skin","Skin Ageing","Face Aging\u002FPhoto Aging of Moderate Grade","Face Skin Photoaging",[67,68,62,69],"Face Skin","Postbiotics","Skin ageing","2026-01-08",{"date":72,"type":36},"2026-01-15",{"date":74,"type":22},"2026-02",{"date":76,"type":22},"2026-05",{"name":78,"class":79},"AB Biotics, SA","INDUSTRY",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100617910","clinical-study-to-assess-safety-effectiveness-and-in-use-tolerability-of-saffron-extract-capsules-for-improving-skin-health-and-reducing-signs-of-aging-on-healthy-adult-male-and-female-subjects-100617910","NCT07324759","Clinical Study to Assess Safety, Effectiveness and In-Use Tolerability of Saffron Extract Capsules for Improving Skin Health and Reducing Signs of Aging on Healthy Adult Male and Female Subjects.","Effect of Saffron Extract Capsule Supplement on Skin Rejuvenation and Anti-Ageing in Healthy Adult Male and Female Subjects: Randomised, Double-Blind, Two-Group, Prospective, Multi-Centre Exploratory Study","GLOW","Inclusion Criteria:\n\n1. Age: 30 to 55 years (both inclusive) at the time of consent.\n2. Sex: Adult male and female having wrinkles and fine lines at crow feet's area, facial hyperpigmentation and dark spots such as tan, pimple marks, sunspots, age spots, uneven skin tone on both side of face.\n3. Females of childbearing potential should have a self-reported negative urine pregnancy test at the time of screening visit.\n4. Subjects should not have used any cosmetic, nutraceutical or therapeutic products for skin ageing in last 1 month.\n5. Subjects must be willing to stop using any cosmetics or any medical products for skin ageing for the duration of the study.\n6. Subjects are not allowed to participate in any other study until this study is complete.\n7. Subjects must be willing and able to follow the study directions and to return for all specified visits with the product.\n8. Subjects must agree to record each use of the test products in the subject's diary card on daily basis.\n9. Subjects must agree to record medication use during the study.\n\nExclusion Criteria:\n\n1. Subjects who are on steroids for last six months and using immunosuppressive, anti-inflammatory, or hormone-modulating medications that may interfere with study outcomes.\n2. Subjects who have used any cosmetic, nutraceutical or therapeutic products for skin last one months.\n3. Subjects currently using any oral supplement and topical products containing kojic acid, glycolic acid, niacinamide, alpha arbutin, vitamin C, retinoids, peptides, exfoliating acids, or any other skin-lightening, anti-ageing, or depigmenting agents within the past 4 weeks.\n4. Subjects with a known history of hypersensitivity, allergic reactions, or intolerance (such as drowsiness, stomach discomfort, nausea, or vomiting).\n5. Subjects with other dermatologic diseases whose presence or products could interfere with the assessment of study.\n6. Subjects that are pregnant and\u002For breastfeeding.\n7. The subject has a known allergy or sensitivity to product ingredients.\n8. Subjects if do not agree to limit sun exposure to affected areas such as face during prolonged sun exposure.\n9. The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject.\n10. The subject has any of the conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results.\n11. The subject is currently taking or has taken any medication, which the Investigator believes may influence the interpretation of the data.\n12. Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.","55 Years",{"count":90,"type":22},50,[59],"This is a randomized, double-blind, comparative, two-arm, prospective, interventional, multi-centre clinical study to evaluate the safety, efficacy, and in-use tolerability of test products, standardized saffron extract capsules, on skin rejuvenation and age-defying benefits in healthy adult male and female subjects.",[94,28,95,96],"Wrinkles","Hyperpigmentation","Dark Spots","2025-12-24",{"date":99,"type":36},"2026-01-07",{"date":101,"type":22},"2026-01-01",{"date":103,"type":22},"2026-05-30",{"name":105,"class":43},"NovoBliss Research Pvt Ltd",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":119,"conditions":120,"keywords":128,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100582895","phase-1-autologous-adipose-cells-therapy-100582895","NCT06869252","Autologous Adipose Cells Therapy","Inclusion Criteria:\n\n1. Outpatients who express interest in skin rejuvenation, and\u002For who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring.\n2. Outpatients who are experiencing hair loss or hair thinning\n3. Provision of signed and dated informed consent form\n4. Clearly stated willingness to comply with all the procedures of the study and availability of the study\n5. Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Known allergic reaction to components of cell culture media\n3. Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures\n4. Chronic infections, e.g. skin fungi infection, psoriasis\n5. Chronic wound healing\n6. Currently taking hormone therapy\n7. History of cancers and active cancers\n8. Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.","21 Years","80 Years",{"count":115,"type":22},40,[117,118],"PHASE1","PHASE2","Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.",[121,122,123,28,124,125,126,127],"Hair Loss\u002FBaldness","Wrinkle Appearance","Volume","Skin Elasticity","Hair Thinning","Skin Pigmentation","Skin Texture",[129,130],"Adipose Cells","Adipocytes","RECRUITING","2025-05-30",{"date":134,"type":36},"2025-05-31",{"date":136,"type":22},"2025-08-01",{"date":138,"type":22},"2026-02-01",{"name":140,"class":79},"CERM INC.",2]